RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow & its faculty.

Who talks to their neighbour? +SSA / Ro talk differently to nearby cells in #SjD #salivary #glands vs NEG Ro SjD Ro52 acts differently than Ro60 ?implications for Rx response? 🤷‍♀️ #ACR25 @RheumNow @ACRheum #Sjogren’s Abst#1684 #ACRBest! Elegant work from Sara McCoy https://t.co/UWUKAxi0UW

• https://x.com/Janetbirdope/status/1982889390893592682/photo/1
• https://x.com/Janetbirdope/status/1982889390893592682/photo/1
• https://x.com/Janetbirdope/status/1982889390893592682/photo/1

How many patients do you need to treat to prevent one RA conversion in at-risk individuals? APPIPRA and ALTO Interception studies, long term data Number Necessary to Treat to prevent 1 RA conversion across time: 1yr = 4 2yrs = 7 3, 4, 5 yrs = 9 6 yrs = 11 #ACR25 #ABSTRACT1678 https://t.co/GBzUJG8jVk

• https://x.com/AurelieRheumo/status/1982889500755013700/photo/1
• https://x.com/AurelieRheumo/status/1982889500755013700/photo/1

DYK? A bipartite ilium is a common SIJ variant. More common among women. SpA mimics involving biomechanical stress: BME & sclerosis 🔸OCI - assoc w/ multiparity, obesity 🔸Degenerative dse #ACR25 @RheumNow https://t.co/IoZepAJKJ6

• https://x.com/RHEUMarampa/status/1982890019326189849/photo/1
• https://x.com/RHEUMarampa/status/1982890019326189849/photo/1

So who with inflamm arthralgias might benefit from abatacept, in terms of delaying RA onset? ALTO study (APIPPRA continuation) 1y abatacept then follow If autoAb x5 (RF, ACPA IgG, IgA, anti-CarP, AAPA): sustained delay of RA If not: benefit only on Rx #ACR25 ABST1678 @RheumNow https://t.co/3Pc5ZLzVf6

• https://x.com/drdavidliew/status/1982890389179896280/photo/1
• https://x.com/drdavidliew/status/1982890389179896280/photo/1
• https://x.com/drdavidliew/status/1982890389179896280/photo/1

#ACR25 Abstr#1401 Sjogren’s #SjD is definitely not a benign disease! Real world study using US database showed high disease burden within 12 mths of diagnosis (i.e. healthcare resource use). GC use was high (~50%). Better therapy is needed to improve outcomes @RheumNow https://t.co/MI3vQ5LByr

• https://x.com/Yuz6Yusof/status/1982890576099066259/photo/1

TNFi induction first year in RA leads to: - less D2T RA at 5y - more sustained remission from 10y onward - less DMARD utilization - less healthcare utilization in these real-world matched cohorts given biosimilar prices, this might be worth considering #ACR25 ABST1677 @RheumNow https://t.co/uL9nHtLkXZ

• https://x.com/drdavidliew/status/1982887013096550530/photo/1
• https://x.com/drdavidliew/status/1982887013096550530/photo/1
• https://x.com/drdavidliew/status/1982887013096550530/photo/1
• https://x.com/drdavidliew/status/1982887013096550530/photo/1

#ACRBest @RheumNow https://t.co/K8kmlzIjxt

• https://twitter.com/AurelieRheumo/status/1982878622647230939

Early TNFi treatment leads to -Less D2T at 5 yrs -More sustained remission at 10yrs -Less bDMARD escalation at 5yrs -More DMARD free remission at 5yrs and 10 yrs -20% reduction annual healths costs -11 mo delay in ttmt escalation Safety data were not presented #ACR25 https://t.co/jPMGUGPtqP

• https://x.com/AurelieRheumo/status/1982886011811111053/photo/1
• https://x.com/AurelieRheumo/status/1982886011811111053/photo/1

SELECT-COMPARE RA UPA vs. ADA What do we learn from 7 years data? Not much Patients who did well on the first drug, keep doing well Patients who required switching for primary failure don't do as well, w/ 26% pts reaching DAS remission in UPA + MTX vs. 16% in ADA + MTX gp No https://t.co/JLUTRZuZOm

• https://x.com/AurelieRheumo/status/1982883419899195532/photo/1
• https://x.com/AurelieRheumo/status/1982883419899195532/photo/1
• https://x.com/AurelieRheumo/status/1982883419899195532/photo/1

Primary CNS vasculitis: what else causes vessel wall enhancement on dedicated brain MRI? From Dr. Hajj-Ali https://t.co/v5ZtyezX3x

• https://x.com/Dr_Brian_MD/status/1982550364974109168/photo/1

At the Global Rheum Summit, patients called for care that values people, not just disease. ✅ Respect lived experience ✅ Enable shared decisions ✅ Support education & coordination of care decisions. @RheumNow #ACR25

~1 in 6 pts with #sarcoidosis May have #cardiac involvemt 1/3 respond to #MTX + #steroids Followed by repeat #PET Failures get 👇 #infliximab >#adalimumab 👇 #JAKi Better survival >yrs ago R heart involved ⬆️risk of MTX nonresponse #ACR25 @RheumNow @ACRheum abst#1664 #ACRbest https://t.co/kYt9JRNSVH

• https://x.com/Janetbirdope/status/1982882247314419752/photo/1
• https://x.com/Janetbirdope/status/1982882247314419752/photo/1